Inspyr Therapeutics, Inc. (GNSZ)


Other OTC - Other OTC Delayed Price. Currency in USD
0.130.00 (0.00%)
At close: 11:37 AM EDT
People also watch:
TPIVFALCSNGXCYDYGOVX
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open0.00
Prev Close0.13
Bid0.00 x
Ask0.00 x
Day's Range0.00 - 0.00
52wk Range
1y Target EstN/A
Market Cap5.43M
P/E Ratio (ttm)-1.07
BetaN/A
Volume0
Avg Vol (3m)25,322
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Business Wire27 days ago

    GenSpera Announces Name Change to Inspyr Therapeutics

    GenSpera, Inc. , a clinical-stage biotechnology company developing a novel prodrug therapeutic for the treatment of cancer, announces that it will change its corporate name to Inspyr Therapeutics, Inc.

  • Business Wire5 months ago

    GenSpera Announces Management Changes

    GenSpera, Inc. , a biotech company developing a novel prodrug therapeutic for the treatment of cancer, announces that Craig A. Dionne, Ph.D., has resigned as GenSpera’s Chairman of the Board and as a Director, and has submitted a notice of termination as GenSpera’s CEO and CFO, all effective immediately.

  • Business Wire6 months ago

    GenSpera Engages FLG Partners LLC and Partner Chris Lowe for Strategic Business Advisory Services

    GenSpera, Inc. , a biotech company developing a novel prodrug therapeutic for the treatment of cancer, announces that the Company’s board of directors has engaged FLG Partners, LLC and its partner Chris Lowe to provide strategic advice to further complement the Company’s efforts to strengthen its corporate and clinical development.